DE69628025D1 - Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus - Google Patents
Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismusInfo
- Publication number
- DE69628025D1 DE69628025D1 DE69628025T DE69628025T DE69628025D1 DE 69628025 D1 DE69628025 D1 DE 69628025D1 DE 69628025 T DE69628025 T DE 69628025T DE 69628025 T DE69628025 T DE 69628025T DE 69628025 D1 DE69628025 D1 DE 69628025D1
- Authority
- DE
- Germany
- Prior art keywords
- creatine
- compounds
- analogues
- act
- glucose metabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title abstract 4
- 208000018914 glucose metabolism disease Diseases 0.000 title 1
- 102000004420 Creatine Kinase Human genes 0.000 abstract 3
- 108010042126 Creatine kinase Proteins 0.000 abstract 3
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- AMHZIUVRYRVYBA-UHFFFAOYSA-N 2-(2-amino-4,5-dihydroimidazol-1-yl)acetic acid Chemical compound NC1=NCCN1CC(O)=O AMHZIUVRYRVYBA-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102100023153 Sodium- and chloride-dependent creatine transporter 1 Human genes 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 108010007169 creatine transporter Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54089495A | 1995-10-11 | 1995-10-11 | |
| US540894 | 1995-10-11 | ||
| PCT/US1996/016365 WO1997013507A1 (en) | 1995-10-11 | 1996-10-11 | Use of creatine analogues for the treatment of disorders of glucose metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69628025D1 true DE69628025D1 (de) | 2003-06-12 |
| DE69628025T2 DE69628025T2 (de) | 2004-04-01 |
Family
ID=24157358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69628025T Expired - Fee Related DE69628025T2 (de) | 1995-10-11 | 1996-10-11 | Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6075031A (de) |
| EP (1) | EP0854712B1 (de) |
| JP (1) | JPH11513671A (de) |
| AT (1) | ATE239462T1 (de) |
| AU (1) | AU721190B2 (de) |
| CA (1) | CA2231632C (de) |
| DE (1) | DE69628025T2 (de) |
| WO (1) | WO1997013507A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1719510A1 (de) * | 1994-11-08 | 2006-11-08 | Avicenda Group, Inc. | Verwendung von Kreatin oder Kreatinanalogen zur Behandlung von Erkrankungen des Nervensystems |
| US7150880B2 (en) * | 1996-05-31 | 2006-12-19 | The Original Creatine Patent Co. Ltd. | Compositions containing creatine and creatinine and a methyl xanthine |
| US6274161B1 (en) * | 1996-05-31 | 2001-08-14 | The Howard Foundation | Compositions containing creatine in suspension |
| US8128955B2 (en) * | 1996-05-31 | 2012-03-06 | The Original Creatine Patent Company | Food compositions containing creatine |
| US6524611B2 (en) | 1996-05-31 | 2003-02-25 | The Howard Foundation | Compositions containing creatine and creatinine |
| JP2002510604A (ja) * | 1998-04-02 | 2002-04-09 | アビセナ グループ， インク． | クレアチン化合物及び第二物質の組み合わせを含む組成 |
| US20060128671A1 (en) * | 1998-04-02 | 2006-06-15 | The General Hospital Corporation | Compositions containing a combination of a creatine compound and a second agent |
| US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
| DK1100488T3 (da) * | 1998-07-28 | 2003-08-11 | Synthes Ag | Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv |
| US20010041187A1 (en) * | 1998-10-20 | 2001-11-15 | Carl W Hastings | Performance-enhancing dietary supplement |
| US6242491B1 (en) * | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
| US6444695B1 (en) | 2000-09-21 | 2002-09-03 | The Regents Of The University Of California | Inhibition of thrombin-induced platelet aggregation by creatine kinase inhibitors |
| AU2003234146A1 (en) * | 2002-04-22 | 2003-11-03 | Experimental And Applied Sciences, Inc. | Food supplements containing 4-hydroxyisoleucine and creatine |
| US20120245211A1 (en) * | 2002-06-04 | 2012-09-27 | Children's Hospital Medical Center | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism |
| EP2567705A3 (de) * | 2002-06-04 | 2013-07-03 | Avicena Group, Inc. | Verfahren zur Behandlung kognitiver Dysfunktion durch Modulation des Energiestoffwechsels des Gehirns |
| WO2004078117A2 (en) * | 2003-02-28 | 2004-09-16 | E-L Management Corp. | Method for increasing hair growth |
| GB0411985D0 (en) * | 2004-05-28 | 2004-06-30 | Howard Foundation Holdings Ltd | Food compositions containing creatine |
| DE102004036047A1 (de) * | 2004-07-24 | 2006-02-23 | Bioghurt Biogarde Gmbh & Co. Kg | Physiologisch aktive Zusammensetzung |
| EP2023914A4 (de) * | 2006-05-11 | 2009-11-11 | Avicena Group Inc | Verfahren zur behandlung eines nervenleidens mit kreatinmonohydrat |
| WO2007146086A1 (en) * | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Creatine prodrugs, compositions and uses thereof |
| WO2007146088A1 (en) * | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Salicyl alcohol creatine phosphate prodrugs, compositions and uses thereof |
| US20070281983A1 (en) * | 2006-06-06 | 2007-12-06 | Xenoport, Inc. | Creatine analog prodrugs, compositions and uses thereof |
| WO2007146085A2 (en) * | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Creatine phosphate prodrugs, compositions and uses thereof |
| US7683043B2 (en) * | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| DE102007004781A1 (de) * | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels |
| WO2008124151A2 (en) * | 2007-04-09 | 2008-10-16 | Avicena Group, Inc. | Use of creatine compounds for the treatment of eye disorders |
| EP2416770B1 (de) | 2009-04-06 | 2016-10-26 | Crearene Ltd. | Lösungen für die hämodialyse und peritonealdialyse enthaltend eine oder mehrere kreatin-verbindungen |
| WO2012149352A1 (en) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| EP3137447B1 (de) | 2014-04-30 | 2021-06-30 | Rgenix, Inc. | Hemmer des kreatintransport und verwendungen davon |
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| US20180071261A1 (en) * | 2015-03-10 | 2018-03-15 | Lumos Pharma, Inc. | Cyclocreatine microsuspension |
| CA3082184A1 (en) | 2017-12-01 | 2019-06-06 | Ultragenyx Pharmaceutical Inc. | Creatine prodrugs, compositions and methods of use thereof |
| CA3161341A1 (en) | 2019-12-11 | 2021-06-17 | Masoud Fakhr Tavazoie | Methods of treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA891509A (en) * | 1972-01-25 | Beecham Group Limited | Esters and amides of guanidine aliphatic acids | |
| GB1153424A (en) * | 1965-04-15 | 1969-05-29 | Horlicks Ltd | Pharmaceutical Compositions |
| GB1195199A (en) * | 1966-11-25 | 1970-06-17 | Horlicks Pharmaceuticals Ltd | Improvements in Compositions comprising Insulin. |
| GB1195200A (en) * | 1967-02-07 | 1970-06-17 | Horlicks Pharmaceuticals Ltd | Pharmaceutical Compositions. |
| GB1552179A (en) * | 1976-11-02 | 1979-09-12 | Beecham Group Ltd | Pharmaceutical compositions for treating hyperglycaemia |
| US5077313A (en) * | 1988-11-25 | 1991-12-31 | Gert Lubec | Process for inhibiting pathological collagen cross-linking in diabetes patients |
| US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| US5321030A (en) * | 1989-02-14 | 1994-06-14 | Amira, Inc. | Creatine analogs having antiviral activity |
| WO1990009192A1 (en) * | 1989-02-14 | 1990-08-23 | Massachusetts Institute Of Technology | Inhibiting transformation of cells having elevated purine metabolic enzyme activity |
| AU7316591A (en) * | 1990-02-28 | 1991-09-18 | Upjohn Company, The | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders |
| US5091404A (en) * | 1990-10-05 | 1992-02-25 | Elgebaly Salwa A | Method for restoring functionality in muscle tissue |
| AU6165894A (en) * | 1993-01-28 | 1994-08-15 | Trustees Of The University Of Pennsylvania, The | Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth |
-
1996
- 1996-10-11 WO PCT/US1996/016365 patent/WO1997013507A1/en active IP Right Grant
- 1996-10-11 AT AT96936418T patent/ATE239462T1/de not_active IP Right Cessation
- 1996-10-11 JP JP9515252A patent/JPH11513671A/ja active Pending
- 1996-10-11 DE DE69628025T patent/DE69628025T2/de not_active Expired - Fee Related
- 1996-10-11 CA CA002231632A patent/CA2231632C/en not_active Expired - Fee Related
- 1996-10-11 AU AU74427/96A patent/AU721190B2/en not_active Ceased
- 1996-10-11 EP EP96936418A patent/EP0854712B1/de not_active Expired - Lifetime
-
1997
- 1997-08-19 US US08/914,887 patent/US6075031A/en not_active Expired - Lifetime
-
2002
- 2002-10-25 US US10/281,379 patent/US20030232793A1/en not_active Abandoned
-
2005
- 2005-06-22 US US11/159,590 patent/US20050256134A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU721190B2 (en) | 2000-06-29 |
| AU7442796A (en) | 1997-04-30 |
| US20050256134A1 (en) | 2005-11-17 |
| CA2231632A1 (en) | 1997-04-17 |
| ATE239462T1 (de) | 2003-05-15 |
| US20030232793A1 (en) | 2003-12-18 |
| CA2231632C (en) | 2004-01-20 |
| EP0854712B1 (de) | 2003-05-07 |
| WO1997013507A1 (en) | 1997-04-17 |
| US6075031A (en) | 2000-06-13 |
| JPH11513671A (ja) | 1999-11-24 |
| EP0854712A1 (de) | 1998-07-29 |
| DE69628025T2 (de) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69628025D1 (de) | Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus | |
| Wang et al. | Regulation of NMDA receptors by tyrosine kinases and phosphatases | |
| Martin | Regulatory properties of brain glutamate decarboxylase | |
| ATE209921T1 (de) | Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust | |
| BR9814984A (pt) | Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio | |
| BR0308537A (pt) | Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga | |
| BR0307871A (pt) | Proteìnas contendo domìnio de folistatina | |
| ES2191066T3 (es) | Preparacion enantioselectiva de sulfoxidos farmaceuticamente activos por biooxidacion. | |
| AU4151996A (en) | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | |
| ATE409466T1 (de) | Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen | |
| DE69232008T2 (de) | Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN | |
| BR9809965B1 (pt) | processo de purificaÇço de Ácido lÁctico. | |
| NZ510920A (en) | Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans | |
| BR9508295A (pt) | Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina | |
| EP1143955A3 (de) | Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes | |
| ATE264392T1 (de) | Verfahren zur herstellung von d-pantoinsäure und d-pantothensäure oder deren salze | |
| Handlogten et al. | Incomplete correspondence between repressive and substrate action by amino acids on transport systems A and N in monolayered rat hepatocytes. | |
| Lumeng et al. | Suppression of the mitochondrial oxidation of (-)-palmitylcarnitine by the malate-aspartate and alpha-glycerophosphate shuttles. | |
| AU587054B2 (en) | Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration | |
| BR9810444A (pt) | Tratamento de diabete com rosiglitazona e insulina | |
| DE69331546D1 (de) | Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen | |
| ES2090703T3 (es) | Medicamento agudo que contiene flurbiprofeno y su empleo. | |
| Nickols et al. | Potentiation of cholera toxin-stimulated cyclic AMP production in cultured cells by inhibitors of RNA and protein synthesis. | |
| HU9501777D0 (en) | Method of treatment of chronic prostatitis with 17-beta-monosubstituted-carbamoly-4-aza-5-alpha-androst-1-en-3-ones | |
| AU4530796A (en) | Treating disorders characterised by excessive cell proliferation with sclareolide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |